UFP Technologies delivered a calendar second quarter marked by strong, broad-based growth across its MedTech platform, which exceeded Wall Street’s revenue and profit expectations. Management pointed to robust performance in key submarkets such as cardiovascular, infection control, and orthopedics, as well as continued diversification across customer programs. CEO Mitchell Rock, in his first earnings call as chief executive, emphasized that growth this quarter was not tied to any one customer or product, highlighting the company’s diversified exposure and execution across multiple medical end markets. Investments in capacity, particularly in the Dominican Republic, have begun to yield operational benefits, even as some program transfers are progressing more slowly than anticipated.
Is now the time to buy UFPT? Find out in our full research report (it’s free for active Edge members).
UFP Technologies (UFPT) Q2 CY2026 Highlights:
- Revenue: $174 million vs analyst estimates of $159.4 million (15.1% year-on-year growth, 9.1% beat)
- Adjusted EPS: $2.92 vs analyst estimates of $2.56 (14.2% beat)
- Adjusted EBITDA: $36.39 million vs analyst estimates of $32.65 million (20.9% margin, 11.5% beat)
- Operating Margin: 16.2%, in line with the same quarter last year
- Market Capitalization: $2.43 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From UFP Technologies’s Q2 Earnings Call
-
Brett Fishbin (KeyBanc Capital Markets) asked for more detail on which submarkets and trends drove the quarter’s strength. CEO Mitchell Rock highlighted cardiovascular, infection control, patient handling, and orthopedics, while noting that the robotic surgical market was flat to down.
-
Justin Ages (CJS Securities) questioned whether the current level of SG&A is sustainable. CFO Ronald Lataille confirmed that SG&A should remain at current levels, with some relief expected once CEO transition costs cycle out by mid-2027.
-
Justin Ages (CJS Securities) also asked about the acquisition pipeline and focus areas. Rock responded that the company is reviewing five to ten opportunities, primarily in surfaces and support and infection control, with a disciplined approach to valuation.
-
Andrew Harris Cooper (Raymond James) inquired about backlog normalization and labor issues at AJR. Rock confirmed that both the backlog and labor challenges are resolved, and that the St. Charles facility is fully ramped, with remaining transfers to the Dominican Republic awaiting customer sign-off.
-
Maxwell Michaelis (Lake Street) sought color on growth outside the top five MedTech customers and specific new program ramp-ups, including robotics. Rock noted nearly 20% growth outside top customers and that new robotics programs are ramping, with more significant contributions expected in the coming year.
Catalysts in Upcoming Quarters
In the coming quarters, the StockStory team will be monitoring (1) the pace and successful completion of key customer program transfers to the Dominican Republic, (2) the scaling and profitability of recently launched and ramping customer programs, and (3) the company’s ability to maintain broad-based growth across diversified medical submarkets. We will also track any material acquisition activity and management’s execution on integrating new leadership hires.
UFP Technologies currently trades at $313.83, up from $267.53 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).
The Best Stocks for High-Quality Investors
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.
